Schäfer, Niklas ; Proescholdt, Martin ; Steinbach, Joachim P ; Weyerbrock, Astrid ; Hau, Peter 
; Grauer, Oliver ; Goldbrunner, Roland ; Friedrich, Franziska ; Rohde, Veit ; Ringel, Florian ; Schlegel, Uwe ; Sabel, Michael ; Ronellenfitsch, Michael W ; Uhl, Martin ; Grau, Stefan ; Hänel, Mathias ; Schnell, Oliver ; Krex, Dietmar ; Vajkoczy, Peter ; Tabatabai, Ghazaleh ; Mack, Frederic ; Schaub, Christina ; Tzaridis, Theophilos ; Nießen, Michael ; Kebir, Sied ; Leutgeb, Barbara ; Urbach, Horst ; Belka, Claus ; Stummer, Walter ; Glas, Martin ; Herrlinger, Ulrich
; Grauer, Oliver ; Goldbrunner, Roland ; Friedrich, Franziska ; Rohde, Veit ; Ringel, Florian ; Schlegel, Uwe ; Sabel, Michael ; Ronellenfitsch, Michael W ; Uhl, Martin ; Grau, Stefan ; Hänel, Mathias ; Schnell, Oliver ; Krex, Dietmar ; Vajkoczy, Peter ; Tabatabai, Ghazaleh ; Mack, Frederic ; Schaub, Christina ; Tzaridis, Theophilos ; Nießen, Michael ; Kebir, Sied ; Leutgeb, Barbara ; Urbach, Horst ; Belka, Claus ; Stummer, Walter ; Glas, Martin ; Herrlinger, Ulrich 
Abstract
Background: The GLARIUS trial, which investigated the efficacy of bevacizumab (BEV)/irinotecan (IRI) compared with standard temozolomide in the first-line therapy of O-6-methylguanine-DNA methyltransferase (MGMT)nonmethylated glioblastoma, showed that progression-free survival was significantly prolonged by BEV/IRI, while overall survival was similar in both arms. The present report focuses on ...
Owner only: item control page
Altmetric